Imatinib 400 mg has been the first-line therapy for chronic myeloid leukemia (CML) since 2001 but may have been licensed at too low a dose. A recent study compared the standard dose with higher doses in patients with newly diagnosed CML and found no difference in response rates at 12 months. But, is the devil in the detail?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
US Department of Health and Human Services http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2001/21335ltr.pdf (2001).
Shah, N. P. et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J. Clin. Oncol. 26, 3204–3212 (2008).
Druker, B. J. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408–2417 (2006).
Cortes, J. E. et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J. Clin. Oncol. 28, 424–430 (2010).
Marin, D. et al. Adherence is the critical factor for achieving molecular responses in chronic myeloid leukemia patients who achieve complete cytogenetic responses on imatinib. J. Clin. Oncol. doi: 10.1200/JCO.2009.26.3087.
Sokal, J. E. et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 63, 789–799 (1984).
Baccarani, M. et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood 113, 4497–4504 (2009).
Yong, A. S., Szydlo, R. M., Goldman, J. M., Apperley, J. F. & Melo, J. V. Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. Blood 107, 205–212 (2006).
Radich, J. P. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc. Natl Acad. Sci. USA 103, 2794–2799 (2006).
Saglio, G. et al. Nilotinib demonstrates superior efficacy compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase: results from the international randomized phase III ENESTnd trial [abstract]. Blood 114, LBA–1 (2009).
Acknowledgements
The author is grateful for support from the NIHR Biomedical Research Centre funding scheme.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
Jane Apperley has received honoraria for speaking at symposia organised by Novartis and has been a member of some of their advisory boards.
Rights and permissions
About this article
Cite this article
Apperley, J. Imatinib—should we have more of a good thing?. Nat Rev Clin Oncol 7, 303–304 (2010). https://doi.org/10.1038/nrclinonc.2010.68
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2010.68
